June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Changes in choroidal thickness in myopic children with 0.01% atropine or the combination therapy of orthokeratology and atropine
Author Affiliations & Notes
  • Saiko Matsumura
    Ophthalmology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan
  • Takashi Itokawa
    Ophthalmology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan
  • Momoko Kawakami
    Ophthalmology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan
  • Tadashi Matsumoto
    Ophthalmology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan
  • Hitoshi Ishikawa
    Orthoptics and Visual Science, School of Allied Health Sciences, Kitasato University, Sagamihara, Kanagawa, Japan
  • Yuichi Hori
    Ophthalmology, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Saiko Matsumura None; Takashi Itokawa None; Momoko Kawakami None; Tadashi Matsumoto None; Hitoshi Ishikawa None; Yuichi Hori ALCON, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4163. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saiko Matsumura, Takashi Itokawa, Momoko Kawakami, Tadashi Matsumoto, Hitoshi Ishikawa, Yuichi Hori; Changes in choroidal thickness in myopic children with 0.01% atropine or the combination therapy of orthokeratology and atropine. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4163.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate changes in choroidal thickness (CT) and axial length (AL) by 0.01% atropine (AT) or the combination therapy of orthokeratology (OKA) and 0.01% AT among Japanese myopic children.

Methods : We retrospectively analyzed changes of CT and AL among myopic children who received 0.01% AT or the combination therapy of OKA and 0.01% AT at Toho University Omori Hospital between January 2021 and December 2022 (N=38 eyes, 8.3 ± 2.1 years old in the 0.01% AT group, and N= 38 eyes, 8.4 ± 1.6 years old in the OKA group). Comprehensive ophthalmologic examinations were performed at baseline, 3 months (M), 6 M, and 12 M later. The enhanced depth imaging mode on the SS-OCT was used to obtain images of the choroid. Measurements were taken at the subfoveal region, 500μm nasal, temporal, superior and inferior to the fovea, and 1000 μm nasal, temporal, superior and inferior to the fovea. We also examined the relationship between the change of CT and the change of AL.

Results : The change of subfoveal CT increased in the OKA group more than in the AT group at 3 M (25.00 ± 18.73 μm vs 14.08 ± 18.54 μm, P < 0.05), 6 M (25.12 ± 21.35 μm vs 6.47 ±21.34 μm, P < 0.001), and 12 M (26.23 ± 16.10 μm vs 1.06 ±29.54 μm, P < 0.001). Compared to the AT group, the OKA group also had thicker choroid in the nasal, temporal, superior and inferior at 6M and 12M (P<0.01). AL increase was less in the OKA group than in the AT group at 6 M (0.10 ± 0.16 mm vs 0.28 ± 0.17 mm, P < 0.001) and 12 M (0.14 ± 0.21mm vs 0.42 ± 0.26 mm, P < 0.001). Subfoveal CT change and AL change were negatively correlated at 6 M (r=-0.47, P < 0.001) and 12 M (r=-0.56, P < 0.001).

Conclusions : The combination therapy group showed more increase in CT compared to the AT group. The increase in CT may influence the inhibition of AL elongation.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×